Related Experiment Video

Updated: Jun 14, 2025

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.4K

Author Correction: Cell-mediated exon skipping normalizes dystrophin expression and muscle function in a new mouse

Francesco Galli1, Laricia Bragg2, Maira Rossi2

  • 1Division of Cell Matrix Biology & Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. francessco.galli@manchester.ac.uk.

EMBO Molecular Medicine
|September 6, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.2K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.0K

Related Experiment Videos

Last Updated: Jun 14, 2025

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.4K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.2K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.0K

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K

Articles linked to this work by shared authors, journal, and citation graph.

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.

Nature communications·2026

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Clinical lung cancer·2026

Assessing the preclinical progress in the therapeutic targeting of axial spondyloarthritis.

Expert opinion on therapeutic targets·2026

N-glycans in non-malignant tumor microenvironment cells dampen CAR-T cell function in solid tumors.

Journal for immunotherapy of cancer·2026

Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs.

Molecular therapy. Advances·2026

Niclosamide reprograms macrophages and improves muscle integrity in Duchenne muscular dystrophy models.

Biochemical pharmacology·2026

Microbiome-host communication via vaccenic acid modulates LRH-1/NR5A2 activity and ameliorates metabolic liver disease.

EMBO molecular medicine·2026

Targeted AAV gene therapy for neuroblastoma via direct capsid-antibody coupling.

EMBO molecular medicine·2026

Comprehensive functional testing in fibroblasts has strong utility to diagnose mitochondrial disease.

EMBO molecular medicine·2026

FFAR2 activation induces IL-22-dependent intestinal immune responses to suppress CNS autoimmunity.

EMBO molecular medicine·2026

New thinking for the next generation of antimalarials.

EMBO molecular medicine·2026

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.

EMBO molecular medicine·2026

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

British journal of haematology·2026

Tat-dependent protein translocation and its evolution.

FEMS microbiology reviews·2026

Theranostics in the management of prostate cancer: from concept to clinical practice.

Expert review of clinical pharmacology·2026

miR-324-5p acts as an independent prognostic biomarker and inhibits pediatric medulloblastoma progression by targeting HOXA9.

Nucleosides, nucleotides & nucleic acids·2026

Th1-biased iNKT cell agonist-loaded liposomal peptide vaccines synergize with a PD-L1 inhibitor to boost immunotherapy against gastric cancer.

Chemical communications (Cambridge, England)·2026

Nanoparticle-Based Delivery Strategies for Targeted Protein Degradation.

Advanced healthcare materials·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us